Skip to content
Trial Eligibility
Menu

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142

This study is recruiting at 20 US sites in 15 states, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Clear Cell Renal Cell Carcinoma

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Xencor, Inc.
Last updated on ClinicalTrials.gov
August 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Arizona · 1

  • Xencor Investigative Site · Phoenix, AZ

California · 2

  • Xencor Investigative Site · Duarte, CA
  • Xencor Investigative Site · Sacramento, CA

Connecticut · 1

  • Xencor Investigative Site · New Haven, CT

Florida · 1

  • Xencor Investigative Site · Jacksonville, FL

Georgia · 1

  • Xencor Investigative Site · Atlanta, GA

Illinois · 2

  • Xencor Investigative Site · Chicago, IL
  • Xencor Investigative Site · Chicago, IL

Kentucky · 1

  • Xencor Investigative Site · Louisville, KY

Minnesota · 1

  • Xencor Investigative Site · Rochester, MN

New Jersey · 1

  • Xencor Investigative Site · New Brunswick, NJ

New York · 2

  • Xencor Investigative Site · New York, NY
  • Xencor Investigative Site · New York, NY

North Carolina · 2

  • Xencor Investigative Site · Charlotte, NC
  • Xencor Investigative Site · Durham, NC

Ohio · 2

  • Xencor Investigative Site · Cincinnati, OH
  • Xencor Investigative Site · Columbus, OH

Oklahoma · 1

  • Xencor Investigative Site · Oklahoma City, OK

Tennessee · 1

  • Xencor Investigative Site · Nashville, TN

Washington · 1

  • Xencor Investigative Site · Seattle, WA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.